新五豐(600975.SH):擬設立控股子公司 投建年產24萬噸飼料廠項目
格隆匯12月15日丨新五豐(600975.SH)公佈,公司擬與東安縣美麗鄉村建設投資開發有限公司(“東安建投”)共同出資設立東安新五豐生物飼料科技有限公司。東安新五豐注冊資金4000萬元,其中:新五豐以貨幣方式出資2800萬元,佔股份總數70%;東安建投以貨幣方式出資1200萬元,佔股份總數30%。
本次設立完成後,東安新五豐投資新建年產24萬噸飼料廠項目,項目生產規模為年生產飼料24萬噸,項目總建設用地面積約42.17畝。
項目總投資7142萬元(建設投資+鋪底流動資金),其中建設投資7025萬元,鋪底流動資金117萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.